Cell Growth & Differentiation, Vol 3, Issue 7 401-411, Copyright © 1992 by American Association of Cancer Research

ARTICLES

A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells

SS Bacus, E Huberman, D Chin, K Kiguchi, S Simpson, M Lippman and R Lupu
Cell Analysis Systems, Inc., Elmhurst, Illinois 60126.

The human erbB-2 oncogene encodes a tyrosine kinase receptor. A ligand for the erbB-2 receptor (gp30), with an apparent molecular weight of 30,000, was reported to modulate the growth of cells overexpressing erbB-2. Whereas low concentrations of gp30 induced proliferation of these cells, higher concentrations inhibited their growth. To elucidate the cellular mechanisms underlying cell growth inhibition by gp30, we tested the effect of this ligand on cell growth and differentiation of the human breast cancer cells AU-565 and MDA-MB-453 (which overexpress erbB-2) and MCF-7 cells (which express low levels of this protooncogene). Ligand concentrations that inhibited growth in cells overexpressing erbB-2 induced apparent differentiation of cells with a more mature phenotype, i.e., with characteristics such as inhibited cell growth, altered cytoplasmic and nuclear morphology, and increased synthesis of milk components (casein and lipids). No significant effect of the ligand was observed in the human breast cancer cell line MCF-7. Concomitant with the induction of differentiation in AU-565 and MDA-MB-453 cells, the erbB-2 protein was translocated from membrane to the cytoplasm and perinuclear sites. These findings indicate that ligand-induced growth inhibition in cells overexpressing erbB-2 is associated with an apparent induction of differentiation.

This article has been cited by other articles:

				S.-M. Feng, C. I. Sartor, D. Hunter, H. Zhou, X. Yang, L. S. Caskey, R. Dy, R. S. Muraoka-Cook, and H. S. Earp III The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell Proliferation Mol. Endocrinol., August 1, 2007; 21(8): 1861 - 1876. [Abstract] [Full Text] [PDF]

				D. K. Giri, M. Ali-Seyed, L.-Y. Li, D.-F. Lee, P. Ling, G. Bartholomeusz, S.-C. Wang, and M.-C. Hung Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor Mol. Cell. Biol., December 15, 2005; 25(24): 11005 - 11018. [Abstract] [Full Text] [PDF]

				S. Rentschler, J. Zander, K. Meyers, D. France, R. Levine, G. Porter, S. A. Rivkees, G. E. Morley, and G. I. Fishman Neuregulin-1 promotes formation of the murine cardiac conduction system PNAS, August 6, 2002; 99(16): 10464 - 10469. [Abstract] [Full Text] [PDF]

				T. A. Santore, Y. Chen, M. J. Smit, and R. Iyengar Adenovirus-directed expression of Q227L-Galpha s inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice PNAS, January 17, 2002; (2002) 32661999. [Abstract] [Full Text] [PDF]

				H. You, W. Yu, B. G. Sanders, and K. Kline RRR-{alpha}-Tocopheryl Succinate Induces MDA-MB-435 and MCF-7 Human Breast Cancer Cells to Undergo Differentiation Cell Growth Differ., September 1, 2001; 12(9): 471 - 480. [Abstract] [Full Text] [PDF]

				C. I. Sartor, H. Zhou, E. Kozlowska, K. Guttridge, E. Kawata, L. Caskey, J. Harrelson, N. Hynes, S. Ethier, B. Calvo, et al. HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells Mol. Cell. Biol., July 1, 2001; 21(13): 4265 - 4275. [Abstract] [Full Text] [PDF]

				X.-F. Le, R. Vadlamudi, A. McWatters, D. S. Bae, G. B. Mills, R. Kumar, and R. C. Bast Jr. Differential Signaling by an Anti-p185HER2 Antibody and Heregulin Cancer Res., July 1, 2000; 60(13): 3522 - 3531. [Abstract] [Full Text]

				X.-F. Le, A. McWatters, J. Wiener, J.-Y. Wu, G. B. Mills, and R. C. Bast Jr. Anti-HER2 Antibody and Heregulin Suppress Growth of HER2-Overexpressing Human Breast Cancer Cells through Different Mechanisms Clin. Cancer Res., January 1, 2000; 6(1): 260 - 270. [Abstract] [Full Text]

				C. K. Tang, X.-Z. W. Concepcion, M. Milan, X. Gong, E. Montgomery, and M. E. Lippman Ribozyme-mediated Down-Regulation of ErbB-4 in Estrogen Receptor-positive Breast Cancer Cells Inhibits Proliferation Both in Vitro and in Vivo Cancer Res., October 1, 1999; 59(20): 5315 - 5322. [Abstract] [Full Text] [PDF]

				R. Emkey and C. R. Kahn Cross-talk between Phorbol Ester-mediated Signaling and Tyrosine Kinase Proto-oncogenes. I. ACTIVATION OF PROTEIN KINASE C STIMULATES TYROSINE PHOSPHORYLATION AND ACTIVATION OF ErbB2 AND ErbB3 J. Biol. Chem., December 5, 1997; 272(49): 31172 - 31181. [Abstract] [Full Text] [PDF]

				R. S. Carver, P. M. Mathew, and W. E. Russell Hepatic Expression of ErbB3 Is Repressed by Insulin in a Pathway Sensitive to PI-3 Kinase Inhibitors Endocrinology, December 1, 1997; 138(12): 5195 - 5201. [Abstract] [Full Text] [PDF]

				S. Zrihan-Licht, J. Lim, I. Keydar, M. X. Sliwkowski, J. E. Groopman, and H. Avraham Association of Csk-homologous Kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in Breast Cancer Cells J. Biol. Chem., January 17, 1997; 272(3): 1856 - 1863. [Abstract] [Full Text] [PDF]

				R. S. Carver, M. X. Sliwkowski, S. Sitaric, and W. E. Russell Insulin Regulates Heregulin Binding and ErbB3 Expression in Rat Hepatocytes J. Biol. Chem., June 7, 1996; 271(23): 13491 - 13496. [Abstract] [Full Text] [PDF]

				F. D. Cirisano and B. Y. Karlan The Role of the HER-2/neu Oncogene in Gynecologic Cancers Reproductive Sciences, May 1, 1996; 3(3): 99 - 105. [Abstract] [PDF]

				C. Sweeney, D. Fambrough, C. Huard, A. J. Diamonti, E. S. Lander, L. C. Cantley, and K. L. Carraway III Growth Factor-specific Signaling Pathway Stimulation and Gene Expression Mediated by ErbB Receptors J. Biol. Chem., June 15, 2001; 276(25): 22685 - 22698. [Abstract] [Full Text] [PDF]

				T. A. Santore, Y. Chen, M. J. Smit, and R. Iyengar Adenovirus-directed expression of Q227L-Galpha s inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice PNAS, February 5, 2002; 99(3): 1671 - 1676. [Abstract] [Full Text] [PDF]